N/A
N=207
Pre-incisional Wound INfiltration and Hypogastric PLEXus Block Using Ropivacaine in Laparoscopic Myomectomy
Fibroid Uterus · Pain, Postoperative
Bottom Line
View on ClinicalTrials.gov: NCT06429163 ↗Enrolled (actual)
207
Serious AEs
0.0%
Results posted
Jan 2026
Primary outcome: Primary: Pain Score — 2; 2; 4 NRS score (0-10 scale)
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Troacar site infiltration (Procedure); Superior hypogastric plexus block (Procedure)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- Female
- Sponsor
- Saint Petersburg State University, Russia
- Primary completion
- Jan 2025
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Pain Score |
2; 2; 4 | — |
| SECONDARY Pain Score Dynamics |
2.5; 3.0; 4.0; 2.0; 2.0; 3.0 | — |
| SECONDARY Mobilization |
5.0; 7.0; 7.0 | — |
| SECONDARY Opioid Use |
3; 14; 22 | — |
| SECONDARY Pain Localisation (Superficial/Deep) |
30; 15; 21; 41; 53; 53 | — |
Summary
The purpose of this study is to assess an impact of laparoscopic superior hypogastric plexus (SHP) block combined with preemptive troacar site infiltration on postoperative pain intensity following laparoscopic myomectomy.
Eligibility Criteria
Inclusion Criteria
- Women aged ≥18 years.
- Indication for laparoscopic myomectomy due to ≥6 cm fibroid(s) or multiple fibroids.
- Ability to provide informed consent.
Exclusion Criteria
- FIGO type 7 subserosal pedunculated myoma.
- Conversion to laparotomy.
- Severe presacral adhesions preventing safe SHPB.
- Concomitant pelvic or abdominal surgery.
Data sourced from ClinicalTrials.gov (NCT06429163). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.